Show results for
Refine by
Industries served
- Medical / Health Care
- Chemical & Pharmaceuticals
- Monitoring and Testing
- Environmental
- University / Academia / Research
- Manufacturing, Other
- Mining
- Aerospace & Air Transport
- Glassware
- Oil, Gas & Refineries
- Water and Wastewater
- Health and Safety
- Air and Climate
- Government
- Food and Beverage
- Energy
- Construction & Construction Materials
Leukemia Suppliers Serving Ohio
59 companies found
Premium
based inDueren, GERMANY
Since 2005, NIPPON Genetics EUROPE has stood for innovation and quality in biotechnology. In these two decades, we have evolved from a supplier of high quality Japanese technologies to a developer of our own groundbreaking solutions. Our products ...
Enables long term cell storage at -80°C or -196°C. Improved cell recovery and viability after thawing. Ready-to-use freezing media – no programmed or sequential freezing required. Serum-free – no risk of contamination. GMP ...
based inSalt Lake City, UTAH (USA)
Echelon Biosciences, Inc (EBI) was founded as Echelon Research Labs by two professors from the University of Utah. Their initial goal was to advance the science of lipid signaling by developing novel research reagents, assays, and ultimately ...
based inAmsterdam, NETHERLANDS
Founded in 1997, Kiadis Pharma is a fully integrated biopharmaceutical company committed to developing innovative, personalized, next-generation cell-based immunotherapies for patients with life threatening diseases. With headquarters in Amsterdam, ...
Ushering in the Future of NK-cell Therapy: Natural killer (NK) cells have long been known to play a significant role in the body’s innate immune response. They were first described in the 1970s, but only in the last 15 years has significant ...
based inSouth San Francisco, CALIFORNIA (USA)
Senti Bio was founded to create a new generation of smarter medicines that outmaneuver complex diseases using novel and unprecedented approaches. Senti Bio designs and optimizes gene circuits, which are created from novel and proprietary ...
Pursuing an Unmet Need in the Treatment of AML - SENTI-202 is designed to target and eliminate acute myeloid leukemia cells while sparing healthy bone marrow. Our vision is a potential medicine that does not rely on an invasive bone ...
based inSeattle, WASHINGTON (USA)
Aptevo Therapeutics is a biotech company focused on bringing novel immuno-oncology therapeutics to market. We leverage the innovative ADAPTIR™ and ADAPTIR-FLEX platform technologies to create therapeutic candidates designed to improve outcomes for ...
APVO436 is an optimized ADAPTIR bispecific antibody candidate designed to redirect T-cell cytotoxicity through the dual targeting of CD3, a T-cell co-receptor that promotes cytotoxicity, and CD123, a cell surface receptor highly expressed in several ...
based inScottsdale, ARIZONA (USA)
Tesis Biosciences’ unique integrated medical platform is revolutionizing targeted genetic sequencing. Our mission is to change medicine by providing physicians, hospitals, and researchers with the tools to help patients treat and overcome major ...
CGx Testing is a preventative gene test that looks for specific inherited changes (mutations) in a person’s genetic make-up. Harmful mutations may increase a persons’ chance, or risk, of developing a disease such as cancer. These ...
based inSeocho-gu, SOUTH KOREA
Taking the first step in 1945, JW Group has found the market for domestic therapeutic drug based on its philosophy of respecting life and pioneering spirit. We are strengthening our global market competitiveness by developing leading health care ...
Active Ingredients: cyclophosphamide 50mg per 1 ...
based inMont-Saint-Guibert, BELGIUM
Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. We are developing a diversified pipeline of allogeneic and autologous CAR T cell ...
The manufacturing facility has been instrumental over the past few years in implementing multiple chemistry, manufacturing, and control (CMC) amendments associated with our CAR T programs, including our proprietary OptimAb manufacturing process for ...
based inWoodland Hills, CALIFORNIA (USA)
EntroGen offers end-to-end molecular diagnostic solutions by providing hardware, reagents and software. Starting from automated nucleic acid extraction and culminating in genomic interpretation with proprietary software embedded for key decision ...
Mutations in IDH1/2 can lead to the development and/or progression of various types of cancer including secondary glioblastomas and acute myeloid leukemias (AML). IDH1/2 mutations are linked to abnormal histone and DNA methylation ...
based inShirley, NEW YORK (USA)
Creative Bioarray is a leading customer-centered biotechnology company and a pioneer with the latest technology of cell patterning. Creative Bioarray has an experienced expert team and is committed to providing comprehensive services and customized ...
NOMO-1 established from the bone marrow of a 31-year-old woman with acute myeloid leukemia (AML FAB M5a) at 2nd relapse; described to show strong lysozyme activity in the cytoplasm, phagocytic activities, and cells are responsive to ...
based inNew Haven, CONNECTICUT (USA)
Precipio is a cancer diagnostics reference laboratory, delivering the latest in advanced diagnostics and personalized medicine. Our goal is to assist oncologists in providing the best care for their patients. At the intersection of academia, cancer ...
Precipio’s HemeScreen acute myeloid leukemia AML Panel offerings are in vitro diagnostic assays that screen for clinically actionable somatic mutations in targets of interest related to AML. This Research Use Only (RUO) assay ...
based inNew York, NEW YORK (USA)
IN8bio was founded in 2016 with the mission of developing novel therapies to address cancer. The company is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T-cell product ...
INB-100, our DeltEx Allo, is an allogeneic product candidate, initially developed for the treatment of patients with acute leukemia undergoing hematopoietic stem cell transplantation (HSCT). This is the first clinical trial of an ...
based inOlivos, ARGENTINA
With a strong development platform and four production sites, AMEGA Biotech develops and produces biosimilars. Exporting recombinant proteins worldwide and focused on central markets registrations, AMEGA Biotech is the leading regional producer.. ...
Interferon alfa is the type that has been found to be most useful in the treatment of certain forms of cancer, including metastatic renal cell carcinoma and hairy cell leukemia. Interferon alfa-2b was also the first molecule to be ...
based inSeattle, WASHINGTON (USA)
AVM Biotechnology is developing and advancing AVM0703, a proprietary formulation of concentrated dexamethasone. This formulation permits the very high dosing necessary to activate the release and trigger the production of the body’s supercharged ...
AVM0703 Induces & Mobilizes Gamma Delta+ NKT-Cells. AVM0703 triggers the production and release of gamma delta+ Natural Killer T-cells (AVM-NKT). These supercharged immune cells have unique properties and appear rapidly in the blood following a ...
based inPlanegg, GERMANY
MorphoSys is a commercial-stage biopharmaceutical company dedicated to the discovery, development, and delivery of innovative cancer medicines. At MorphoSys, our ambition is to redefine how cancer is treated. As a commercial-stage biopharmaceutical ...
It is therefore considered as a potential target for the treatment of B cell malignancies, such as non-Hodgkin’s lymphoma (NHL), including diffuse large B cell lymphoma (DLBCL), indolent lymphomas like follicular lymphoma (FL) and marginal ...
based inOlathe, KANSAS (USA)
TVAX Biomedical is a clinical stage development company advancing its novel targeted cell-based immunotherapy for the treatment of cancer. TVAX Biomedical is developing a paradigm-shifting cancer treatment that offers the promise of improved ...
TVAX Biomedical is developing an exciting new approach to cancer treatment that offers the promise of improved clinical outcomes, low toxicity and the potential for fundamentally changing the way cancer is ...
based inGaithersburg, MARYLAND (USA)
NexImmune is a clinical-stage biotechnology company developing unique approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation (AIMâ„¢) technology. AIM nanoparticles act as synthetic dendritic cells to deliver ...
based inNew York, NEW YORK (USA)
We are a biopharmaceutical company developing transformational therapeutics targeting serious diseases with significant unmet medical needs. Our mission is to improve patient outcomes and save lives. To achieve our mission, we seek to capitalize on ...
Our licensed gene therapy, CO-sTiRNA™, is a dual-action STAT3 inhibitor. STAT3 is a gene that drives tumor cell growth and anti-tumor immune suppression. CO-sTiRNA™ is a highly selective and targeted gene therapy that silences the ...
based inBoston, MASSACHUSETTS (USA)
AVEO is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for cancer patients. AVEO™s strategy is to focus its resources toward development and commercialization of its product candidates in ...
based inNorth Brunswick, NEW JERSEY (USA)
Ascendia Pharmaceuticals specializes in the invention and development of specialty pharmaceutical products and novel formulation technologies. We provide formulation, analytical, and manufacturing services to pharmaceutical companies, working ...